AnaptysBio, Inc.
ANAB
$59.43
-$0.56-0.93%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -7.98% | 151.08% | 154.26% | 102.93% | 286.84% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -7.98% | 151.08% | 154.26% | 102.93% | 286.84% |
| Cost of Revenue | 3.27% | -39.99% | -25.60% | -9.94% | -88.10% |
| Gross Profit | -10.10% | 15,680.53% | 468.29% | 49.85% | 178.24% |
| SG&A Expenses | 85.44% | 54.89% | -3.34% | 14.14% | 14.52% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 8.83% | -21.66% | -21.14% | -5.57% | 12.01% |
| Operating Income | -25.77% | 791.84% | 252.50% | 35.10% | 34.74% |
| Income Before Tax | -34.51% | 328.06% | 146.00% | 17.28% | 10.59% |
| Income Tax Expenses | -9.09% | 1,450.00% | -- | 333.33% | -- |
| Earnings from Continuing Operations | -34.47% | 327.75% | 146.00% | 17.21% | 10.49% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -34.47% | 327.75% | 146.00% | 17.21% | 10.49% |
| EBIT | -25.77% | 791.84% | 252.50% | 35.10% | 34.74% |
| EBITDA | -25.97% | 803.75% | 254.09% | 35.20% | 34.84% |
| EPS Basic | -43.62% | 349.57% | 147.76% | 21.39% | 21.71% |
| Normalized Basic EPS | -43.67% | 349.88% | 147.76% | 21.45% | 21.80% |
| EPS Diluted | -43.62% | 321.16% | 145.61% | 21.39% | 21.71% |
| Normalized Diluted EPS | -43.67% | 321.55% | 145.81% | 21.45% | 21.80% |
| Average Basic Shares Outstanding | -6.37% | -- | -3.67% | 5.32% | 14.34% |
| Average Diluted Shares Outstanding | -6.37% | -4.70% | 0.43% | 5.32% | 14.34% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |